Overview

* Steris ( STE ) fiscal Q2 revenue grows 10%

* Adjusted EPS for fiscal Q2 exceeds analyst estimates

* Company raises fiscal 2026 outlook for organic revenue and adjusted EPS

Outlook

* Company raises fiscal 2026 constant currency organic revenue growth to 7-8%

* STERIS ( STE ) expects fiscal 2026 adjusted EPS to be $10.15-$10.30

* Company anticipates fiscal 2026 free cash flow of approximately $850 mln

Result Drivers

* HEALTHCARE SEGMENT - Healthcare revenue grew 9% driven by service and consumable sales, offset by tariff costs and inflation

* APPLIED STERILIZATION TECHNOLOGIES - AST revenue rose 10% with growth in service revenue despite a decline in capital equipment sales

* LIFE SCIENCES SEGMENT - Life Sciences revenue increased 13%, led by 39% growth in capital equipment sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $2.47 $2.35 (8

Adjusted Analysts

EPS )

Q2 Beat $244.50 $230.96

Adjusted mln mln (5

Net Analysts

Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for STERIS plc ( STE ) is $280.00, about 13.6% above its November 4 closing price of $241.85

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)